New combo vaccine aims to shield seniors from RSV and HMPV

NCT ID NCT06556147

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new vaccine called VXB-241 in healthy adults aged 60-83, with a smaller group of younger adults (18-40) first. The vaccine is designed to protect against two viruses that can cause serious lung infections: RSV and HMPV. Researchers will check how safe the vaccine is and how well it boosts the immune system, using four different dose levels. Some participants will get a booster shot about a year later to see if revaccination is helpful.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Show contact details

Locations

University of the Sunshine Coast

Morayfield, Queensland, 4506, Australia
University of the Sunshine Coast

Sippy Downs, Queensland, 4556, Australia
University of the Sunshine Coast

South Brisbane, Queensland, 4101, Australia
Veritus Research

Bayswater, Victoria, 3153, Australia